<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01874535</url>
  </required_header>
  <id_info>
    <org_study_id>GERD A and B</org_study_id>
    <nct_id>NCT01874535</nct_id>
  </id_info>
  <brief_title>Rate of Complete Symptom Relief, Prevention of Symptom Relapse: Grades A and B Esophagitis of Esomeprazole Therapy</brief_title>
  <official_title>The Rates of Complete Symptom Relief,Prevetion of Symptom Relapse and Maintenance of Esophagitis Healing for 4-week Versus 8-week Esomeprazole Therapy Among Los Angeles Grades A and B Erosive Esophagitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the impact of initial treatment duration (4-week versus 8-week)of Esomeprazole
      (40mg) on the rate of symptom relapse and sustained healing of esophagitis in patients with
      symptomatic erosive esophagitis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients:

      Patients between the ages of 15 and 80 years with clinical symptoms of acid regurgitation,
      heart burn, or feeling of acidity in the stomach, who have Los Angeles Grade A and B erosive
      esophagitis proven by endoscopy are recruited. Criteria for exclusions include (1)
      coexistence of peptic ulcer or gastrointestinal malignancies, (2) pregnancy, (3) coexistence
      of serious concomitant illness (for example, decompensated liver cirrhosis and uremia), (4)
      previous gastric surgery, (5) allergy to esomeprazole, (6) symptom score of a validated
      questionnaire (Chinese GERDQ) less than 12, and (7) equivocal endoscopic diagnosis of Los
      Angeles Grade A and B erosive esophagitis.

      Outcome parameters:

      The main outcome measures

        1. Rate of complete symptom relief (CSR) at the end of initial treatment phase

        2. rate of symptom relapse within 12 weeks after stopping initial therapy
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Rates of Complete Symptom Relief</measure>
    <time_frame>at the 20 weeks after the end of initial treatment.</time_frame>
    <description>Rate of complete symptom relief (CSR) at the end of initial treatment phase</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">408</enrollment>
  <condition>Erosive Esophagitis</condition>
  <arm_group>
    <arm_group_label>GERD Los Angeles A and B-4 week group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with Los Angeles A and B esophagitis prescribed with esomeprazole (40 mg)daily- 4 week group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GERD Los Angeles A and B-8-week group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with Los Angeles A and B esophagitis prescribed with esomeprazole (40 mg)daily- 8 week group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole 40 mg</intervention_name>
    <description>Comparison of 4-weeks and 8-weeks initial treatment duration of esomeprazole 40 mg per day on the rate of symptom relapse and sustained healing of esophagitis in patients with symptomatic erosive esophagitis</description>
    <arm_group_label>GERD Los Angeles A and B-4 week group</arm_group_label>
    <arm_group_label>GERD Los Angeles A and B-8-week group</arm_group_label>
    <other_name>Nexium 40mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients between the ages of 15 and 80 years

          -  with clinical symptoms of acid regurgitation, heart burn, or feeling of acidity in the
             stomach,

          -  who have Los Angeles Grade A and B erosive esophagitis proven by endoscopy are
             recruited.

        Exclusion Criteria:

          1. coexistence of peptic ulcer or gastrointestinal malignancies,

          2. pregnancy,

          3. coexistence of serious concomitant illness (for example, decompensated liver cirrhosis
             and uremia),

          4. previous gastric surgery,

          5. allergy to esomeprazole,

          6. symptom score of a validated questionnaire (Chinese GERDQ) less than 12, and

          7. equivocal endoscopic diagnosis of Los Angeles Grade A and B erosive esophagitis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seng-Kee Chuah, M.D</last_name>
    <role>Study Chair</role>
    <affiliation>Kaohsiung Chang Gung Memorial Hospital,Taiwan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seng-Kee Chuah</name>
      <address>
        <city>Kaohsiung</city>
        <zip>833</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>November 4, 2012</study_first_submitted>
  <study_first_submitted_qc>June 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2013</study_first_posted>
  <results_first_submitted>June 16, 2017</results_first_submitted>
  <results_first_submitted_qc>November 21, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 4, 2018</results_first_posted>
  <last_update_submitted>November 21, 2017</last_update_submitted>
  <last_update_submitted_qc>November 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chang Gung Memorial Hospital</investigator_affiliation>
    <investigator_full_name>Wei-Chen Tai M.D.</investigator_full_name>
    <investigator_title>Attending physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophagitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esomeprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data will be shared in July 2017</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>4-week Group</title>
          <description>Patients with Los Angeles A and B esophagitis prescribed with esomeprazole (40 mg)daily
Esomeprazole 40 mg: Comparison of 4-weeks initial treatment duration of esomeprazole 40 mg per day on the rate of symptom relapse and sustained healing of esophagitis in patients with symptomatic erosive esophagitis</description>
        </group>
        <group group_id="P2">
          <title>8-week Group</title>
          <description>Patients with Los Angeles A and B esophagitis prescribed with esomeprazole (40 mg)daily
Esomeprazole 40 mg: Comparison of 8-weeks initial treatment duration of esomeprazole 40 mg per day on the rate of symptom relapse and sustained healing of esophagitis in patients with symptomatic erosive esophagitis</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="207"/>
                <participants group_id="P2" count="201"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="152"/>
                <participants group_id="P2" count="157"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>incomplete symptom resolution</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline characteristics of the enrolled patients</population>
      <group_list>
        <group group_id="B1">
          <title>4-week Group</title>
          <description>Patients with Los Angeles A and B esophagitis prescribed with esomeprazole (40 mg)daily
Esomeprazole 40 mg: Comparison of 4-weeks initial treatment duration of esomeprazole 40 mg per day on the rate of symptom relapse and sustained healing of esophagitis in patients with symptomatic erosive esophagitis</description>
        </group>
        <group group_id="B2">
          <title>8-week Group</title>
          <description>Patients with Los Angeles A and B esophagitis prescribed with esomeprazole (40 mg)daily
Esomeprazole 40 mg: Comparison of 8-weeks initial treatment duration of esomeprazole 40 mg per day on the rate of symptom relapse and sustained healing of esophagitis in patients with symptomatic erosive esophagitis</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="207"/>
            <count group_id="B2" value="201"/>
            <count group_id="B3" value="408"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.1" spread="12.8"/>
                    <measurement group_id="B2" value="51.1" spread="12.8"/>
                    <measurement group_id="B3" value="51.1" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>sex</title>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="164"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="120"/>
                    <measurement group_id="B2" value="124"/>
                    <measurement group_id="B3" value="244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="207"/>
                    <measurement group_id="B2" value="201"/>
                    <measurement group_id="B3" value="408"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Rates of Complete Symptom Relief</title>
        <description>Rate of complete symptom relief (CSR) at the end of initial treatment phase</description>
        <time_frame>at the 20 weeks after the end of initial treatment.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>4 Week Group</title>
            <description>Patients with Los Angeles A and B esophagitis prescribed with esomeprazole (40 mg)daily
Esomeprazole 40 mg: Comparison of 4-weeks weeks initial treatment duration of esomeprazole 40 mg per day on the rate of symptom relapse and sustained healing of esophagitis in patients with symptomatic erosive esophagitis</description>
          </group>
          <group group_id="O2">
            <title>8 Week Group</title>
            <description>Patients with Los Angeles A and B esophagitis prescribed with esomeprazole (40 mg)daily
Esomeprazole 40 mg: Comparison of 8-weeks initial treatment duration of esomeprazole 40 mg per day on the rate of symptom relapse and sustained healing of esophagitis in patients with symptomatic erosive esophagitis</description>
          </group>
        </group_list>
        <measure>
          <title>The Rates of Complete Symptom Relief</title>
          <description>Rate of complete symptom relief (CSR) at the end of initial treatment phase</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="152"/>
                    <measurement group_id="O2" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Chi-squared</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.009</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>20 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>4 Week Group</title>
          <description>Patients with Los Angeles A and B esophagitis prescribed with esomeprazole (40 mg)daily
Esomeprazole 40 mg: Comparison of 4-weeks initial treatment duration of esomeprazole 40 mg per day on the rate of symptom relapse and sustained healing of esophagitis in patients with symptomatic erosive esophagitis</description>
        </group>
        <group group_id="E2">
          <title>8 Week Group</title>
          <description>Patients with Los Angeles A and B esophagitis prescribed with esomeprazole (40 mg)daily
Esomeprazole 40 mg: Comparison of 8-weeks initial treatment duration of esomeprazole 40 mg per day on the rate of symptom relapse and sustained healing of esophagitis in patients with symptomatic erosive esophagitis</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The trial was performed in a single country</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Seng-Kee Chuah and Dr. Wei-Chen Tai</name_or_title>
      <organization>Kaohsiung Chang Gung Memorial Hospital, Taiwan</organization>
      <phone>886-975056007</phone>
      <email>chuahsk@seed.net.tw</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

